closedosingdownloadefficacymoasafetytable-checktable-cross

The OTEZLA® international website

This site is intended for healthcare professionals outside the U.S.

OTEZLA IMPROVES NAIL PSORIASIS1*

Sustained improvement in nail psoriasis up to 1 year in ESTEEM 11,a

aESTEEM 1 study. Data as observed; includes patients initially randomized to OTEZLA 30 mg BID or placebo at week 0 who were PASI-75 responders at week 32 and continued to receive OTEZLA through week 52.

  • In ESTEEM 1, treatment with OTEZLA resulted in significantly greater improvement in Nail Psoriasis Severity Index (NAPSI) score vs placebo at week 16 (mean percent change from baseline: 22.5% vs 6.5%; P < 0.0001)1†

See the OTEZLA difference

Real psoriasis patients, real pictures.

Baseline

Week 16

Individual results may vary.

Week 32

Individual results may vary.

*In patients with nail psoriasis at baseline (NAPSI score >1; 558/844, 66.1%).

Full analysis set, LOCF.

Actual real-world OTEZLA patient from Celgene Patient Picture Project, 2015. Consent provided to Celgene for use.

Reference:

  1. Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Amer Acad Dermatol. 2015;74(1):134-142.
You are leaving the OTEZLA® (apremilast) website
Do you wish to leave this site?
OTEZLA International Websites
OTEZLA is approved in 51 Countries
  • United States

  • Canada

  • Australia

  • Israel

  • Switzerland

  • New Zealand

  • Austria

  • Belgium

  • Bulgaria

  • Croatia

  • Republic of Cyprus

  • Czech Republic

  • Denmark

  • Estonia

  • Finland

  • France

  • Germany

  • Greece

  • Hungary

  • Ireland

  • Italy

  • Latvia

  • Lithuania

  • Luxembourg

  • Malta

  • Netherlands

  • Poland

  • Portugal

  • Romania

  • Slovakia

  • Slovenia

  • Spain

  • Sweden

  • United Kingdom

  • Norway

  • Iceland

  • Liechtenstein

  • Russia

  • Japan

  • Hong Kong

  • Singapore

  • Kuwait

  • Taiwan

  • UAE

  • Korea

  • Thailand

  • Lebanon

  • Qatar

  • Argentina

  • Mexico

  • Brazil